Working… Menu

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04269200
Recruitment Status : Recruiting
First Posted : February 13, 2020
Last Update Posted : July 8, 2021
The Gynecologic Oncology Group (GOG) Foundation Inc
The European Network for Gynaecological Oncological Trial groups (ENGOT)
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 26, 2023
Estimated Study Completion Date : March 5, 2025